Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 January 2019 | Story Thabo Kessah | Photo Thabo Kessah
Dr Lisa Komoreng
Dr Lisa Komoreng’s research highlights traditional medicinal plant qualities used to deal with diseases like TB and elephantiasis.

The burden that diseases like tuberculosis (TB), lymphatic filariasis (elephantiasis), sexually transmitted infections (STIs), skin infections, and ear, nose and throat (ENT) infections bring to the country, mainly poverty-stricken communities, has prompted Dr Lisa Komoreng to focus her research on traditional medicinal plants.

 

South Africa, says Dr Komoreng, has the third highest number of reported cases and the fifth highest number of estimated prevalent cases, with the second highest burden of drug-resistant TB cases in the world amongst the 22 high-burden countries.

South Africa is burdened
by elephantiasis and treating
it remains a huge problem,
says Dr Lisa Komoreng.

 

“According to the Free State Provincial Strategic Plan (2012-2016), HIV and TB are the leading causes of death in the Province, with TB being the second most leading cause. Our country is also burdened by elephantiasis and treating it remains a huge problem. Patients are often turned away from some of the public hospitals, reasons being that there is no treatment in the country or that the disease needs specialist care. It with this in mind that my research focuses on providing treatment that is cheaper than western medicine, easily accessible, with fewer or no side effects,” she said.

 

“People suffering from elephantiasis are not only physically disabled, but they suffer mental, social and financial losses contributing to stigma and poverty. Some of the drugs used to treat the disease are ineffective against adult parasitic worms, which are the ones that cause the disease, and they also have side effects. Our research in dealing with these diseases enables us to work hand-in-hand with herbalists, traditional healers and people who have indigenous knowledge about the use of traditional medicine. We consult with them in order to acquire information about the medicinal plants that are used to treat and manage those diseases. Once they provide us with information, we collect the plant species together, which we subsequently take to the University herbarium for proper identification of their scientific names and to the laboratory for experiments,” she added.

 

Dr Komoreng is a Senior Lecturer in the Department of Plant Sciences at the Qwaqwa Campus. She has authored and co-authored over 15 research articles and has presented her research at various national and international conferences.  Her research team comprises of 5 MSc and 4 PhD students.

 

The Thuthuka NRF Rating Track (2015 – 2017 and 2018 – 2020) funds the research project on elephantiasis.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept